ECSP067087A - TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA - Google Patents

TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA

Info

Publication number
ECSP067087A
ECSP067087A EC2006007087A ECSP067087A ECSP067087A EC SP067087 A ECSP067087 A EC SP067087A EC 2006007087 A EC2006007087 A EC 2006007087A EC SP067087 A ECSP067087 A EC SP067087A EC SP067087 A ECSP067087 A EC SP067087A
Authority
EC
Ecuador
Prior art keywords
carbonitrils
piridin
inhibitors
protein kinase
compounds
Prior art date
Application number
EC2006007087A
Other languages
English (en)
Inventor
Diane Harris Boschelli
Nan Zhang
Sosa Ana Carolina Barrios
Haris Durutlic
Biqi Wu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP067087(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP067087A publication Critical patent/ECSP067087A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

Esta invención provee los compuestos de la Fórmula II: en la cual:R1, R2 y X son definidos en lo que antecede en la memoria descriptiva, los cuales son útiles en el tratamiento del cáncer, ataque apoplético, infarto de miocardio, dolor neuropático, osteoporosis, enfermedad renal policística, enfermedad autoinmune, artritis reumatoidea, y rechazo de transplantes. La invención también provee procesos para producir dichos compuestos.
EC2006007087A 2004-05-14 2006-12-14 TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA ECSP067087A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/845,710 US7276519B2 (en) 2002-11-25 2004-05-14 Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ECSP067087A true ECSP067087A (es) 2007-01-26

Family

ID=35149207

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007087A ECSP067087A (es) 2004-05-14 2006-12-14 TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA

Country Status (20)

Country Link
US (2) US7276519B2 (es)
EP (1) EP1756117A2 (es)
JP (1) JP2007537262A (es)
KR (1) KR20070015575A (es)
CN (1) CN1950379A (es)
AR (1) AR050248A1 (es)
AU (1) AU2005245820A1 (es)
BR (1) BRPI0511089A (es)
CA (1) CA2564530A1 (es)
CR (1) CR8787A (es)
EC (1) ECSP067087A (es)
GT (1) GT200500109A (es)
MX (1) MXPA06012900A (es)
NO (1) NO20065489L (es)
PA (1) PA8633201A1 (es)
PE (1) PE20060355A1 (es)
RU (1) RU2006137476A (es)
TW (1) TW200602348A (es)
WO (1) WO2005113560A2 (es)
ZA (1) ZA200609422B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1833829A2 (en) 2004-12-23 2007-09-19 F. Hoffmann-Roche AG Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
CN101830899A (zh) * 2004-12-23 2010-09-15 霍夫曼-拉罗奇有限公司 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
US20090306373A1 (en) * 2005-12-20 2009-12-10 Gamber Gabriel G 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
TW200900408A (en) * 2007-03-02 2009-01-01 Kyowa Hakko Kogyo Kk Fused pyridine derivative
WO2009041591A1 (ja) * 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
WO2010036629A2 (en) * 2008-09-26 2010-04-01 National Health Research Institutes Fused multicyclic compounds as protein kinase inhibitors
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
ES2606637T3 (es) * 2012-02-09 2017-03-24 Merck Patent Gmbh Derivados de furo [3,2- b]piridina como inhibidores de TBK1 e IKK
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126970A3 (en) 1983-04-27 1985-11-06 Beecham Group Plc Anxiolytic and anti-depressant thienopyridine derivatives
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
HUP0100287A3 (en) * 1997-11-11 2003-04-28 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
CN1144786C (zh) * 1998-09-29 2004-04-07 美国氰胺公司 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
ATE264328T1 (de) 1999-04-21 2004-04-15 Wyeth Corp Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
ATE353320T1 (de) 1999-12-29 2007-02-15 Wyeth Corp Tricyclische proteinkinasehemmer
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
ATE277933T1 (de) 2000-06-06 2004-10-15 Pfizer Prod Inc Thiophenverbindungen zur verwendung als antikrebsmittel
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
US7253184B2 (en) * 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
EP1418917A1 (en) 2001-08-10 2004-05-19 Novartis AG Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007014616A (es) * 2005-05-20 2009-08-12 Methylgene Inc Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa

Also Published As

Publication number Publication date
CR8787A (es) 2007-10-02
US7276519B2 (en) 2007-10-02
NO20065489L (no) 2006-11-28
PE20060355A1 (es) 2006-05-11
CN1950379A (zh) 2007-04-18
GT200500109A (es) 2005-12-23
MXPA06012900A (es) 2007-01-26
AU2005245820A1 (en) 2005-12-01
PA8633201A1 (es) 2006-05-16
WO2005113560A3 (en) 2006-01-12
RU2006137476A (ru) 2008-06-20
EP1756117A2 (en) 2007-02-28
WO2005113560A2 (en) 2005-12-01
TW200602348A (en) 2006-01-16
BRPI0511089A (pt) 2007-12-26
KR20070015575A (ko) 2007-02-05
CA2564530A1 (en) 2005-12-01
US20080070913A1 (en) 2008-03-20
ZA200609422B (en) 2008-07-30
JP2007537262A (ja) 2007-12-20
US20040242883A1 (en) 2004-12-02
AR050248A1 (es) 2006-10-11

Similar Documents

Publication Publication Date Title
ECSP067087A (es) TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA
ECSP055802A (es) TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS Y TIENO[2,3-b]PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINA CINASAS
PE20151336A1 (es) Inhibidores de la tirosina-quinasa de bruton
BRPI0508622A (pt) compostos de bifenil úteis como antagonistas do receptor muscarìnico
UY27225A1 (es) Inhibidores de la rho-quinasa
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
MX2022010465A (es) Compuestos de degradacion del receptor cinasa relacionado con trompomiosina y metodos de uso.
ECSP056072A (es) Pirimidinonas sustituidas
UY31397A1 (es) Inhibidores de quinasa c-fms
PE20070621A1 (es) 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas
MX2009005194A (es) Derivados de purina 7-sustituidos para inmunosupresion.
CL2008002184A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension pulmonar, osteoporosis, artritis, entre otras.
CO6382183A2 (es) Nuevas piridin -2-onas y piridazin -3-onas sustituidas
PE20070496A1 (es) Compuestos derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina
CR10095A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PA8524101A1 (es) 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS
PE20080931A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
PE20080974A1 (es) Nuevas pirozolopirimidinas como inhibidores de quinasa dependientes de ciclina
CR8749A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
EA200870167A1 (ru) Димерные соединения - агонисты рецепторов fgf (fgfr), способ их получения и их применение в терапии
EA200500899A1 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
EA200801404A1 (ru) Новый способ получения 5-амино-3н-тиазоло[4,5-d]пиримидин-2-она
DE602004014264D1 (de) Verfahren zur herstellung von olanzapin
CY1115760T1 (el) Τικαγρελορη για την θεραπευτικη αγωγη ανευρυσματων κοιλιακης αορτης